Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
CINACALCETHYDROCHLORIDE 99,2 mg/stuk SAMENSTELLING overeenkomend met ; CINACALCET 90 mg/stuk
G.L. Pharma GmbH Schlossplatz 1 A-8502 LANNACH (OOSTENRIJK)
H05BX01
CINACALCETHYDROCHLORIDE 99,2 mg/stuk SAMENSTELLING overeenkomend met ; CINACALCET 90 mg/stuk
Filmomhulde tablet
CELLULOSE, MICROKRISTALLIJN (E 460) ; CROSPOVIDON (E 1202) ; IJZEROXIDE GEEL (E 172) ; INDIGOKARMIJN ALUMINIUMLAK (E 132) ; MACROGOL 4000 ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203) ; POVIDON K 30 (E 1201) ; SILICIUMDIOXIDE (E 551) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171),
Oraal gebruik
Cinacalcet
Hulpstoffen: CELLULOSE, MICROKRISTALLIJN (E 460); CROSPOVIDON (E 1202); IJZEROXIDE GEEL (E 172); INDIGOKARMIJN ALUMINIUMLAK (E 132); MACROGOL 4000; MAGNESIUMSTEARAAT (E 470b); MAÏSZETMEEL, GEPREGELATINEERD; POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203); POVIDON K 30 (E 1201); SILICIUMDIOXIDE (E 551); TALK (E 553 B); TITAANDIOXIDE (E 171);
2017-07-20
Cinacalcet (as hydrochloride) 30, 60, 90 mg Film-coated tablets Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT CINGLAN 30 MG FILMOMHULDE TABLETTEN CINGLAN 60 MG FILMOMHULDE TABLETTEN CINGLAN 90 MG FILMOMHULDE TABLETTEN Cinacalcet READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What [Product name] is and what it is used for 2. What you need to know before you take [Product name] 3. How to take [Product name] 4. Possible side effects 5. How to store [Product name] 6. Contents of the pack and other information 1 WHAT [PRODUCT NAME] IS AND WHAT IT IS USED FOR [Product name] works by controlling the levels of parathyroid hormone (PTH), calcium and phosphorous in your body. It is used to treat problems with organs called parathyroid glands. The parathyroids are four small glands in the neck, near the thyroid gland, that produce parathyroid hormone (PTH). [Product name] is used in adults: to treat secondary hyperparathyroidism in adult patients with serious kidney disease who need dialysis to clear their blood of waste products. to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with parathyroid cancer. to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with primary hyperparathyroidism when removal of the gland is not possible. [Product name] is used in children aged 3 years to less than 18 years of age: to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis t Lees het volledige document
Cinacalcet (as hydrochloride) 30, 60, 90 mg Film-coated tablets Page 1 of 18 1.3.1 Summary of Product Characteristics - Core 1. NAME OF THE MEDICINAL PRODUCT Cinglan 30 mg filmomhulde tabletten Cinglan 60 mg filmomhulde tabletten Cinglan 90 mg filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 30 mg cinacalcet (as hydrochloride). Each tablet contains 60 mg cinacalcet (as hydrochloride). Each tablet contains 90 mg cinacalcet (as hydrochloride). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Green oval biconvex coated tablets (approximately 4.5 x 7 mm), debossed with C9CC on one side and 30 on the other side Green oval biconvex coated tablets (approximately 5.5 x 9 mm), debossed with C9CC on one side and 60 on the other side Green oval biconvex coated tablets (approximately 6.5 x 10.5 mm), debossed with C9CC on one side and 90 on the other side 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Secondary hyperparathyroidism _Adults _ Treatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. _Paediatric population _ Treatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy (see section 4.4). Cinacalcet (as hydrochloride) 30, 60, 90 mg Film-coated tablets Page 2 of 18 [Product name] may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1). Parathyroid carcinoma and primary hyperparathyroidism in adults Reduction of hypercalcaemia in adult patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated. Lees het volledige document